Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet protease-activated receptors (PARs) are a family of G-protein-coupled receptors (GPCRs) that play a central role in platelet activation, aggregation, and the regulation of hemostasis and thrombosis. The main subtypes in human platelets are PAR1 and PAR4, both activated by thrombin. Activation involves proteolytic cleavage by serine proteases, exposure of a tethered ligand, and intramolecular binding to initiate intracellular signaling. PAR1 is a high-affinity thrombin receptor mediating rapid platelet responses, while PAR4 has lower affinity and mediates slower, sustained responses. PARs are therapeutic targets for antithrombotic therapy.
Inhibition of platelet activation by blocking protease-mediated receptor cleavage and activation, or by blocking the tethered ligand binding site.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet Protease-Activated Receptor (PAR).